drugset / Trial / NCT02303431

Phase 1 Pediatric Pharmacokinetics/Pharmacodynamics (PK/PD) Study

NCT02303431

Phase 1 Completed 66 enrolled Daiichi Sankyo
Non-randomizedSingle-groupOpen-labelBasic science

Summary

This is the first evaluation of edoxaban in pediatric subjects. In this Phase 1 study, a single dose of edoxaban will be given to pediatric subjects who require anticoagulant therapy to see what the body does to the drug (pharmacokinetics) and what the drug does to the body (pharmacodynamics), and to compare if these effects are similar to those observed in adults.

Timeline

Start
2014-11-05
Primary completion
2021-09-16
Completion
2021-09-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Edoxaban Small molecule 30 mg
Subject Edoxaban Small molecule 60 mg